Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients by bringing beloranib, a first-in-class novel medicine, to market. Founded in 2005 as a capital efficient company, Zafgen brings together leading experts in obesity and metabolic disease to address the underserved and growing population of patients who are severely obese. Zafgen's singular focus is on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/04/12 | $21,000,000 | Series D |
Alta Partners Atlas Venture Third Rock Ventures | undisclosed |
| 12/04/13 | $45,000,000 | Series E |
Alta Partners Brookside Capital RA Capital Venrock | undisclosed |
